OBJECTIVE

To stablish if the use of tranexamic acid (TXA) in patients with HELLP syndrome improves the clinic curse in general terms.

MATERIALS AND METHODS

Analytic, comparative and retrospective study where two groups of patients are included, which assisted to the obstetrics and gynecology service in the Hospital Universitario de Saltillo, where the diagnosis of HELLP syndrome was made. Tranexamic acid was given to one of the groups versus the control group without the drug.

RESULTS

18 patients were included, 9 in each group. The following was observed respect to the laboratory parameters: platelets greater than 105 vs smaller than 105 in the control group. The lactate dehydrogenase (DHL) had a decrease of 58 vs 16% in the patients without tranexamic acid in the first 48 hours. The aspartate aminotransferase (AST) improved 56 vs 43% in the control group, and the alanine aminotransferase (ALT) improved 31 vs 20% in the control group, both in the first 24 hours. The report of protein quantification in 24 hours was 2867 vs 3378 mg in the control group. The hemoglobin figures remained greater than 11vs 9.92 g/dL of the control group. The days of stay in the intensive care unit (UCI) were 3 vs 4.16 of the control group.

CONCLUSIONS:

Randomized studies are required with an extended sample, to value the benefits and effects of the tranexamic acid, in this kind of patients. According to the collected data the use of tranexamic acid represents an alternative in the treatment of HELLP syndrome, which provides a clinic benefit.